CNTGF (Centogene NV) Other Long-Term Liabilities: $0.75 Mil (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNTGF Centogene NV CNTGF
12 GF Score
Price $0.12
View Full Analysis

What is Centogene NV Other Long-Term Liabilities?

Centogene NV CNTGF 12 Other Long-Term Liabilities is $0.75 Mil as of Dec. 2023. GuruFocus rates CNTGF with a GF Score™ of 12/100.

Centogene NV's other long-term liabilities for the quarter that ended in Dec. 2023 was $0.75 Mil.

Centogene NV's quarterly other long-term liabilities increased from Dec. 2022 ($0.89 Mil) to Jun. 2023 ($1.08 Mil) but then declined from Jun. 2023 ($1.08 Mil) to Dec. 2023 ($0.75 Mil).

Centogene NV's annual other long-term liabilities declined from Dec. 2021 ($1.09 Mil) to Dec. 2022 ($0.89 Mil) and declined from Dec. 2022 ($0.89 Mil) to Dec. 2023 ($0.75 Mil).

Centogene NV Other Long-Term Liabilities Related Terms

Centogene NV Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Centogene NV's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Centogene NV Other Long-Term Liabilities Chart

Centogene NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Long-Term Liabilities
Get a 7-Day Free Trial 0.00 0.78 1.09 0.89 0.75

Centogene NV Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.09 1.26 0.89 1.08 0.75
CNTGF
12GF Score
Centogene NV CNTGF
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Centogene NV Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.75 Mil mean?
Centogene NV (CNTGF) has a Other Long-Term Liabilities of $0.75 Mil as of Dec. 2023. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Centogene NV and its competitors.
Is Centogene NV's Other Long-Term Liabilities too high?
Centogene NV's current Other Long-Term Liabilities is $0.75 Mil. Overall, Centogene NV has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Centogene NV's Other Long-Term Liabilities compare to ISPC and CHEK?
Centogene NV's Other Long-Term Liabilities of $0.75 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Diagnostics & Research company?
A good Other Long-Term Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Centogene NV and its competitors. Centogene NV's current Other Long-Term Liabilities is $0.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centogene NV stock overvalued right now?
Centogene NV (CNTGF) has a current Other Long-Term Liabilities of $0.75 Mil. The current Other Long-Term Liabilities is $0.75 Mil. Centogene NV's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Centogene NV (CNTGF), the current Other Long-Term Liabilities is $0.75 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Centogene NV Business Description

Address Am Strande 7, Rostock, MV, DEU, 18055
Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.
12GF Score

Get the complete analysis for CNTGF

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price